A5045894818- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Immunodeficiency and Autoimmune Disorders
- International Environmental Law and Policies
- Eosinophilic Esophagitis
- Multiple Myeloma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Mast cells and histamine
- Genetics and Neurodevelopmental Disorders
- Parasites and Host Interactions
- PI3K/AKT/mTOR signaling in cancer
- Environmental law and policy
- RNA and protein synthesis mechanisms
- Histone Deacetylase Inhibitors Research
- Genomic variations and chromosomal abnormalities
- Genomics and Rare Diseases
- International Law and Aviation
- Trace Elements in Health
Territoires, Villes, Environnement & Société
2021-2025
Université du littoral côte d'opale
2021-2025
Université de Lille
2013-2024
Inserm
2013-2024
Centre Hospitalier Universitaire de Lille
2011-2024
Hôpital Jeanne de Flandre
2012-2024
Centre National de la Recherche Scientifique
1994-2024
Maison Européenne des Sciences de l'Homme et de la Société
2022
CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers
2022
Université Lille Nord de France
2011-2022
Imatinib (400 mg daily) is considered the best initial therapy for patients with newly diagnosed chronic myeloid leukemia (CML) in phase. However, only a minority of treated imatinib have complete molecular remission.
Aggressive meningiomas that progress after surgery/radiotherapy represent an unmet medical need. Strong and constant expression of SSTR2A receptors activation the Pi3K/Akt/mTOR pathway have been demonstrated in meningiomas. The combination everolimus, mTOR inhibitor, octreotide, a somatostatin agonist, has shown additive antitumor effect vitro. phase II CEVOREM trial investigated efficacy this on recurrent meningiomas.Patients with documented tumor progression ineligible for further were...
The CD3-CD4+ aberrant T-cell phenotype is the most described in lymphoid variant of hypereosinophilic syndrome (L-HES), a rare form HES. Only few cases have been reported, and data for these patients are scarce. To describe characteristics outcome L-HES patients, we conducted national multicentric retrospective study French Eosinophil Network. All who met recent criteria hypereosinophilia (HE) or HES had persistent subset on blood phenotyping were included. Clinical laboratory...
Purpose:TP53 is a tumor-suppressor gene that functions as regulator influencing cellular responses to DNA damage, and TP53 alterations are associated with pejorative outcome in most B-lymphoid disorders. Little known regarding alteration Waldenstrom's macroglobulinemia (WM).Experimental Design: Here, we have explored the incidence of using Sanger sequencing ultradeep-targeted 125 WM 10 immunoglobulin M (IgM) monoclonal gammopathy undetermined significance (MGUS), along clinical features...
The BCR-ABL T315I mutation confers resistance to currently licensed tyrosine kinase inhibitors in chronic myelogenous leukemia. However, the impact of this on survival early stages disease, phase, has never been detailed. Using matched pair analysis, a cohort 64 patients with phase leukemia harboring and resistant imatinib mesylate was compared similar 53 imatinib, but no detectable mutation, pre-ponatinib era. These were according age at diagnosis, interval between disease diagnosis start...
Targeting translation initiation in multiple myeloma induces inhibition of a specific oncogenic program.
BACKGROUND The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off‐treatment response after treatment discontinuation; this situation called treatment‐free remission (TFR). Knowledge accumulated during last 10 years justifies moving TFR strategies from research to clinical practice. METHODS Twenty experts French Chronic Myeloid Leukemia Study Group (France Intergroupe des...
Mantle cell lymphoma (MCL) is usually an aggressive disease. However, a few patients do have “indolent” evolution (iMCL) defined by long survival time without intensive therapy. Many studies highlight the prognostic role of additional genetic abnormalities, but these abnormalities are not routinely tested for and yet influence treatment decision. We aimed to evaluate impact detected conventional cytogenetic testing, as well their relationships with clinical characteristics value in...
We investigated using a custom NGS panel of 149 genes the mutational landscape 64 consecutive adult patients with tyrosine kinase fusion-negative hypereosinophilia (HE)/hypereosinophilic syndrome (HES) harboring features suggestive myeloid neoplasm. At least one mutation was reported in 50/64 (78%) (compared to 8/44 (18%) idiopathic HE/HES/HE